Katie Tuckwell - Concepedia

Author

Katie Tuckwell

Roche (United Kingdom)

Also Known As

K Tuckwell, K. Tuckwell, Katie Tuckwell

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Roche (United Kingdom)Massachusetts General Hospital Harvard University Stanford University Universitat de Barcelona

About

Katie Tuckwell is an author at Roche (United Kingdom) specializing in medicine, vasculitis, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	352
2	Immunology	1	1	71
3	Neurology	1	1	97
4	Orthopaedics	1	1	56
5	Pathology	1	1	71

Katie Tuckwell

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Trial of Tocilizumab in Giant-Cell Arteritis John H. Stone, Katie Tuckwell, Sophie Dimonaco, New England Journal of Medicine	2017	1.3K
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis Cem Gabay, Iain B. McInnes, Arthur Kavanaugh, Annals of the Rheumatic Diseases	2015	148
Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case–control analysis Jessica C. Wilson, Khaled Sarsour, Neil Collinson, Seminars in Arthritis and Rheumatism RheumatologyGlomerulonephritisGlucocorticoid TherapyVasculitisSerious Adverse Effects	2016	128
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial David Isenberg, Richard Furie, Nicholas S. Jones, Arthritis & Rheumatology	2021	126
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial Iván O. Rosas, George Diaz, Robert Gottlieb, Intensive Care Medicine	2021	124
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase <scp>II</scp> Trial Stanley Cohen, Katie Tuckwell, Tamiko R. Katsumoto, Arthritis & Rheumatology	2020	113
Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab John H. Stone, Katie Tuckwell, Sophie Dimonaco, Arthritis & Rheumatology	2019	107
Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK Sara Gale, Jessica C. Wilson, Jenny Chia, Rheumatology and Therapy	2018	105
Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis Michael S. Broder, Khaled Sarsour, Eunice Chang, Seminars in Arthritis and Rheumatism Autoimmune DiseaseVasculitisAutoimmunityNeurologyClaims-based Analysis	2016	97
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial Katie Tuckwell, Neil Collinson, Sophie Dimonaco, Seminars in Arthritis and Rheumatism RheumatologyAutoimmune DiseaseVasculitisGiacta TrialImmunology	2016	71

Page 1